Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
NCT02918292
Completed
This study is a prospective, multicenter phase II study with patients receiving haploidentical transplantation for Severe Aplastic Anemia (SAA). The primary objective is to assess overall survival (OS) at 1 year post-hematopoietic stem cell transplantation (HSCT).
Gender:
ALL
Ages:
75 years and below
Trial Updated:
11/28/2022
Locations: University of Michigan Medical Center, Ann Arbor, Michigan +1 locations
Conditions: Severe Aplastic Anemia
Register for Updates
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
NCT01265849
Completed
The purpose of this study was to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc in a multivitamin (CIZ) combination prior to standard of care therapy (surgery followed by radiotherapy or concurrent radiochemotherapy) is safe and will increase the overall survival of subjects with previously untreated locally advanced primary squamous cell carcinoma of the oral cavity or soft palate at a median of 3 to 5 years
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2022
Locations: Henry Ford Health System Henry Ford Hospital, Detroit, Michigan
Conditions: Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
Register for Updates
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
NCT00822120
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxygluc... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/16/2022
Locations: Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan +32 locations
Conditions: Lymphoma, Nonneoplastic Condition
Register for Updates
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NCT00087178
Completed
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating breast cancer. PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens to compare how well they work in treating women who have undergone surgery for breast cancer that has not spre... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/10/2022
Locations: Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan +34 locations
Conditions: Breast Cancer
Register for Updates
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
NCT01966471
Completed
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2022
Locations: Karmanos Cancer Institute.., Detroit, Michigan +1 locations
Conditions: Breast Cancer
Register for Updates
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00887536
Completed
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this stud... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
04/13/2022
Locations: CCOP, St. Joseph Mercy Hospital, Ann Arbor, Michigan +25 locations
Conditions: Breast Cancer
Register for Updates
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NCT01547741
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2022
Locations: Bixby Medical Center, Adrian, Michigan +50 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
NCT01026220
Completed
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/01/2022
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan +6 locations
Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
NCT00567567
Completed
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/01/2022
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan +8 locations
Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
NCT00075582
Completed
This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which tr... Read More
Gender:
ALL
Ages:
49 years and below
Trial Updated:
11/17/2021
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan +5 locations
Conditions: Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
Register for Updates
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy also work in different ways to kill more cancer cells or stop them from growing. It is not yet known whether rituximab is more effective with combination chemotherapy or bendamustine hydrochloride in treating patients wit... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan +2 locations
Conditions: Lymphoma
Register for Updates
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
NCT00412360
Completed
This study is a Phase III, randomized, open-label, multi-center, prospective study of single umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric patients with hematologic malignancies.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/13/2021
Locations: University of Michigan Medical Center, Ann Arbor, Michigan +1 locations
Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma
Register for Updates